Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]

Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U. Neumann; Jean Michel Pawlotsky; Solko W. Schalm; Stefan Zeuzem; Bart J. Veldt; Bettina E. Hansen; Elke Verhey-Hart; Martin Lagging

doi:10.1002/hep.21505

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]

Esther Lukasiewicz, Kristoffer Hellstrand, Johan Westin, Carlo Ferrari, Avidan U. Neumann, Jean Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Bart J. Veldt, Bettina E. Hansen, Elke Verhey-Hart, Martin Lagging

The Mina and Everard Goodman Faculty of Life Sciences

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	258-259
Number of pages	2
Journal	Hepatology
Volume	45
Issue number	1
DOIs	https://doi.org/10.1002/hep.21505
State	Published - Jan 2007

Access to Document

10.1002/hep.21505

Cite this

Lukasiewicz, E., Hellstrand, K., Westin, J., Ferrari, C., Neumann, A. U., Pawlotsky, J. M., Schalm, S. W., Zeuzem, S., Veldt, B. J., Hansen, B. E., Verhey-Hart, E., & Lagging, M. (2007). Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]. Hepatology, 45(1), 258-259. https://doi.org/10.1002/hep.21505

@article{7a6d872ba57c4cd0937e095e4dd75a66,

title = "Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]",

author = "Esther Lukasiewicz and Kristoffer Hellstrand and Johan Westin and Carlo Ferrari and Neumann, {Avidan U.} and Pawlotsky, {Jean Michel} and Schalm, {Solko W.} and Stefan Zeuzem and Veldt, {Bart J.} and Hansen, {Bettina E.} and Elke Verhey-Hart and Martin Lagging",

year = "2007",

month = jan,

doi = "10.1002/hep.21505",

language = "אנגלית",

volume = "45",

pages = "258--259",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

Lukasiewicz, E, Hellstrand, K, Westin, J, Ferrari, C, Neumann, AU, Pawlotsky, JM, Schalm, SW, Zeuzem, S, Veldt, BJ, Hansen, BE, Verhey-Hart, E & Lagging, M 2007, 'Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]', Hepatology, vol. 45, no. 1, pp. 258-259. https://doi.org/10.1002/hep.21505

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]. / Lukasiewicz, Esther; Hellstrand, Kristoffer; Westin, Johan et al.
In: Hepatology, Vol. 45, No. 1, 01.2007, p. 258-259.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1

T2 - Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]

AU - Lukasiewicz, Esther

AU - Hellstrand, Kristoffer

AU - Westin, Johan

AU - Ferrari, Carlo

AU - Neumann, Avidan U.

AU - Pawlotsky, Jean Michel

AU - Schalm, Solko W.

AU - Zeuzem, Stefan

AU - Veldt, Bart J.

AU - Hansen, Bettina E.

AU - Verhey-Hart, Elke

AU - Lagging, Martin

PY - 2007/1

Y1 - 2007/1

UR - http://www.scopus.com/inward/record.url?scp=33846445632&partnerID=8YFLogxK

U2 - 10.1002/hep.21505

DO - 10.1002/hep.21505

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 17187414

AN - SCOPUS:33846445632

SN - 0270-9139

VL - 45

SP - 258

EP - 259

JO - Hepatology

JF - Hepatology

IS - 1

ER -

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]

Access to Document

Other files and links

Cite this